Orchid Cellmark (ORCH) 8-K Fourth Quarter and Year-End 2009

Fourth Quarter and Year-End 2009

Earnings Conference Call

March 11, 2010

Fourth Quarter and Year-End 2009

Earnings Conference Call

March 11, 2010

Exhibit 99.1

Forward-Looking Statement

Forward-Looking Statement

All statements in this presentation that are not historical are forward-looking statements within the

meaning

of

the

Private

Securities

Litigation

Reform

Act

of

1995.

Such

statements

are

subject

to

the

risks

and uncertainties that could cause actual results to differ materially from those projected, including, but

not limited to, uncertainties relating to the implementation of government contracts, growing through

acquisitions,  the potential value of the “mega tender”, our potential success in the U.K. National

Procurement Plan, expansion of our U.K. facilities, the opportunity for work related to all-arrestee

legislation, the potential of property crime testing, consolidation of our US forensic and paternity facilities,

operating efficiencies, technologies, product development, manufacturing, market acceptance, cost and

pricing of Orchid Cellmark’s products and services, dependence on government funding, competition,

intellectual property of others, patent protection, litigation, and the timing and amount of contracts put up

for bid. These risks and other additional factors affecting these statements and Orchid Cellmark’s

business

are

discussed

under

the

headings

“Risks

Related

to

Our

Business”

and

“Risks

Associated

with

Our

Common

Stock”

in

Orchid

Cellmark’s

Annual

Report

on

Form

10-K

for

the

year

ended

December

31,

2008,

as

amended,

as

filed

with

the

Securities

and

Exchange

Commission,

and

in

other

filings

made

by

Orchid

Cellmark

with

the

Securities

and

Exchange

Commission

from

time

to

time.

Orchid

Cellmark

expressly

disclaims

any

obligation

or

undertaking

to

release

publicly

any

updates

or

revisions

to

any

forward-looking

statements

contained

herein

to

reflect

any

change

in

Orchid

Cellmark’s

expectations

with

regard

thereto

or

any

change

in

events,

conditions,

or

circumstances

on

which

any

such

statements

are

based,

except

as

may

be

required

by

law.

Total Annual Revenue Trend -

Constant Dollars

(in 000’s -

unaudited)

Total Annual Revenue Trend -

Constant Dollars

(in 000’s -

unaudited)

Note:  All revenues calculated using 2008 Fx rates

56,000

58,000

60,000

62,000

64,000

66,000

2006

2007

2008

2009

Historical Annual Net Loss

(in 000’s)

Historical Annual Net Loss

(in 000’s)

(12,000)

(10,000)

(8,000)

(6,000)

(4,000)

(2,000)

0

2004

2005

2006

2007

2008

2009

EBITDA

(in 000’s -

unaudited)

EBITDA

(in 000’s -

unaudited)

(8,000)

(6,000)

(4,000)

(2,000)

0

2,000

4,000

2006

2007

2008

2009

Cash Flow From Operations

(in 000’s)

Cash Flow From Operations

(in 000’s)

(12,000)

(10,000)

(8,000)

(6,000)

(4,000)

(2,000)

0

2,000

4,000

2006

2007

2008

2009

U.S. Laboratories

U.S. Laboratories

Dallas

Forensics

Dayton

Paternity

E.Lansing

Paternity

Nashville

Forensics

U.S. Laboratories

U.S. Laboratories

Dallas

Forensics

Dayton

Paternity

Consolidation

Consolidation

Estimated Annual Cost Savings of $2.4 Million

U.K. Regional Laboratories

U.K. Regional Laboratories

Abingdon HQ

Chorley Facility

Orchid

Orchid

U.S. Sexual Assault Kit Casework Backlog Will

Continue To Grow

U.S. Sexual Assault Kit Casework Backlog Will

Continue To Grow

Orchid Cellmark has contracts with all four of the above agencies and has just

received the first of the Houston PD rape kit backlog

Orchid Cellmark has contracts with all four of the above agencies and has just

received the first of the Houston PD rape kit backlog

•

A Senate hearing to discuss mechanisms for the federal government to help alleviate the rape kit

backlog was held in December.

–

During the hearing, S. 2736 (Justice for Survivors of Sexual Assault Act of 2009), a bill to

reduce the national rape kit backlog and clear the thousands of existing untested rape kits in

police and crime-lab storage facilities.

–

Orchid Cellmark supplied written testimony at the hearing as to how private labs can contribute

to eliminating the backlog

–

The House is now putting together a companion bill for S. 2736

•

At the state level, pressure from victims groups and the recent CBS news reports on the rape kit

backlog is driving significant activity to address this backlog in many states.

–

The

Michigan

State

Police

have

identified

as

many

as

12,000

rape

kits

that

need

to

be

tested

and the Michigan legislature has held formal hearings to determine how to proceed

–

Illinois has legislation pending that requires that all rape kits be tested including those currently

in storage (precise numbers are unknown)

–

The

Birmingham

(AL)

police

department

identified

2,100

rape

kits

in

storage

–

The Houston police department has identified 4,000 rape kits that need to be tested and have

begun the testing process

–

Several other cities were identified by CBS as having a significant number of untested rape kits

U.K. Revenue

U.K. Revenue

£0

£2,000

£4,000

£6,000

£8,000

£10,000

£12,000

£14,000

£16,000

£18,000

£20,000

2006

2007

2008

2009

2009+

Last year of

FAL revenue

NW/SW Award

NW/SW Tender

submitted

Kent, Sussex &

City of London

Awards

1

st

full

year

of

NW/SW Award

plus other

Forensics Drives Growth